Rhinospray Plus nasal spray

Rhinospray is a long-standing brand in the pharmaceutical market, particularly popular in Central Europe for its nasal decongestant properties. Originally developed by the German pharmaceutical giant Boehringer Ingelheim, the brand became a staple in households for treating symptoms of the common cold.

In 2016, as part of a significant asset swap, the brand was acquired by Sanofi. The manufacturing of the product primarily takes place at specialized pharmaceutical sites in Germany to ensure high standards of quality and medical efficacy. The brand remains a key part of the global healthcare portfolio managed by the French multinational firm.

Today, Rhinospray Plus is marketed under the Opella consumer healthcare division of Sanofi. This division focuses on over-the-counter (OTC) products, providing relief for respiratory issues, allergies, and general wellness across various international markets.